National trends in oral anticoagulant use in the United States, 2007 to 2011

Circulation: Cardiovascular Quality and Outcomes

Volumn 5, Issue 5, 2012, Pages 615-621

  Kirley, Kate ^a   Qato, Dima M ^a   Kornfield, Rachel ^a   Stafford, Randall S ^b   Caleb Alexander, G ^a,c,d,e  

^a UNIVERSITY OF CHICAGO   (United States)

^b STANFORD UNIVERSITY   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Anticoagulants; Coumarins; Other anticoagulants

Indexed keywords

ANTITHROMBOCYTIC AGENT; DABIGATRAN; WARFARIN;

ADULT; AGED; AMBULATORY CARE; ANTICOAGULANT THERAPY; ARTICLE; CARDIOLOGY; CLINICAL PRACTICE; DRUG COST; GENERAL PRACTICE; HEALTH CARE COST; HEART ATRIUM FIBRILLATION; HUMAN; INTERNAL MEDICINE; MAJOR CLINICAL STUDY; MONOTHERAPY; OFF LABEL DRUG USE; PRESCRIPTION; PRIORITY JOURNAL; THROMBOEMBOLISM; TREATMENT INDICATION; UNITED STATES;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; AMBULATORY CARE; ANTICOAGULANTS; ANTITHROMBINS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; DRUG COSTS; DRUG PRESCRIPTIONS; DRUG UTILIZATION; DRUG UTILIZATION REVIEW; GUIDELINE ADHERENCE; HEALTH CARE SURVEYS; HEALTH EXPENDITURES; HUMANS; MEDICAL AUDIT; MIDDLE AGED; OFF-LABEL USE; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; PREVENTIVE HEALTH SERVICES; THROMBOEMBOLISM; TIME FACTORS; UNITED STATES; WARFARIN;

EID: 84868662780     PISSN: 19417713     EISSN: 19417705     Source Type: Journal    
DOI: 10.1161/CIRCOUTCOMES.112.967299     Document Type: Article

References (36)

1. Heron M. Deaths: leading causes for 2004. Natl Vital Stat Rep. 2011;59:1-95.
2. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S, Smith SC, Jr., Jacobs AK, Adams CD, Anderson JL, Antman EM, Halperin JL, Hunt SA, Nishimura R, Ornato JP, Page RL, Riegel B, Priori SG, Blanc JJ, Budaj A, Camm AJ, Dean V, Deckers JW, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo JL, Zamorano JL. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation - executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for Management of Patients with Atrial Fibrillation). J Am Coll Cardiol. 2006;48:854-906. (Pubitemid 44175743)
3. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983-988.
4. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857-867. (Pubitemid 351650486)
5. Mueller RL, Scheidt S. History of drugs for thrombotic disease. Discovery, development, and directions for the future. Circulation. 1994;89:432-449. (Pubitemid 24979843)
6. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 Suppl):204S-233S. (Pubitemid 39297955)
7. Zimetbaum PJ, Thosani A, Yu HT, Xiong Y, Lin J, Kothawala P, Emons M. Are atrial fibrillation patients receiving warfarin in accordance with stroke risk? Am J Med. 2010;123:446-453.
8. Brophy MT, Snyder KE, Gaehde S, Ives C, Gagnon D, Fiore LD. Anticoagulant use for atrial fibrillation in the elderly. J Am Geriatr Soc. 2004;52:1151-1156. (Pubitemid 38869075)
9. Hughes B. First oral warfarin alternative approved in the US. Nat Rev Drug Discov. 2010;9:903-906.
10. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-1151.
11. Freeman JV, Zhu RP, Owens DK, Garber AM, Hutton DW, Go AS, Wang PJ, Turakhia MP. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med. 2011;154:1-11.
12. Shah SV, Gage BF. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation. 2011;123:2562-2570.
13. Wann LS, Curtis AB, Ellenbogen KA, Estes NA 3rd, Ezekowitz MD, Jack-man WM, January CT, Lowe JE, Page RL, Slotwiner DJ, Stevenson WG, Tracy CM. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol. 2011;57:1330-1337.
14. You JJ, Singer DE, Howard PA, Lane DA, Eckman MH, Fang MC, Hylek EM, Schulman S, Go AS, Hughes M, Spencer FA, Manning WJ, Halperin JL, Lip GY; American College of Chest Physicians. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e531S-e575S.
15. Alexander GC, O'Connor AB, Stafford RS. Enhancing prescription drug innovation and adoption. Ann Intern Med. 2011;154:833-7, W.
16. FDA New Release - FDA approves Xarelto to reduce risk of blood clots after hip, knee replacements. Posted 7/5/11. Available at: http://www.fda. gov/NewsEvents/Newsroom/PressAnnouncements/ucm261839.htm. Accessed December 15, 2011.
17. FDA New Release - FDA approves Xarelto to prevent stroke in people with common type of abnormal heart rhythm. Posted 11/4/11. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm278646.htm. Accessed December 15, 2011.
18. Zell ER, McCaig LF, Kupronis BA, Besser RE, Schuchat A. A comparison of the national disease and therapeutic index and the national ambulatory medical care survey to evaluate antibiotic usage. Proceedings of the section on survey research methods, American Statistical Association. Alexandria, VA: American Statistical Association. 2000;840-845.
19. Higashi A, Zhu S, Stafford RS, Alexander GC. National trends in ambulatory asthma treatment, 1997-2009. J Gen Intern Med. 2011;26:1465-1470.
20. Stafford RS, Radley DC. The underutilization of cardiac medications of proven benefit, 1990 to 2002. J Am Coll Cardiol. 2003;41:56-61. (Pubitemid 36044404)
21. Alexander GC, Tseng CW. Six strategies to identify and assist patients burdened by out-of-pocket prescription costs. Cleve Clin J Med. 2004;71:433-437. (Pubitemid 38821202)
22. Pham HH, Alexander GC, O'Malley AS. Physician consideration of patients' out-of-pocket costs in making common clinical decisions. Arch Intern Med. 2007;167:663-668. (Pubitemid 46598458)
23. FDA MedWatch - Pradaxa (dabigatran etexilate mesylate): Drug Safety Communication - Safety Review of Post-Market Reports of Serious Bleeding Events. Posted 12/7/11. Available at: http://www.fda.gov/Safety/. Accessed December 12, 2011.
24. Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med. 2012;172:397-402.
25. Alexander GC, Stafford RS. Does comparative effectiveness have a comparative edge? JAMA. 2009;301:2488-2490.
26. Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GY. Underuse of oral anticoagulants in atrial fibrillation: A systematic review. Am J Med. 2010;123:638-645.e4.
27. Go AS, Hylek EM, Borowsky LH, Phillips KA, Selby JV, Singer DE. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med. 1999;131:927-934. (Pubitemid 30005032)
28. Bravata DM, Rosenbeck K, Kancir S, Brass LM. The use of warfarin in veterans with atrial fibrillation. BMC Cardiovasc Disord. 2004;4:18.
29. Oldgren J, Alings M, Darius H, Diener HC, Eikelboom J, Ezekowitz MD, Kamensky G, Reilly PA, Yang S, Yusuf S, Wallentin L, Connolly SJ; RE-LY Investigators. Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: A subgroup analysis of the RE-LY trial. Ann Intern Med. 2011;155:660-7, W204.
30. Gross CP, Vogel EW, Dhond AJ, Marple CB, Edwards RA, Hauch O, Demers EA, Ezekowitz M. Factors influencing physicians' reported use of anticoagulation therapy in nonvalvular atrial fibrillation: A cross-sectional survey. Clin Ther. 2003;25:1750-1764. (Pubitemid 36801946)
31. Schulman S, Parpia S, Stewart C, Rudd-Scott L, Julian JA, Levine M. Warfarin dose assessment every 4 weeks versus every 12 weeks in patients with stable international normalized ratios: A randomized trial. Ann Intern Med. 2011;155:653-9, W201.
32. Agarwal S, Hachamovitch R, Menon V. Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: A meta-analysis. Arch Intern Med. 2012;172:623-631.
33. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ; RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361:2342-2352.
34. Friedman RJ, Dahl OE, Rosencher N, Caprini JA, Kurth AA, Francis CW, Clemens A, Hantel S, Schnee JM, Eriksson BI; RE-MOBILIZE, RE-MODEL, RE-NOVATE Steering Committees. Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: A pooled analysis of three trials. Thromb Res. 2010;126:175-182.
35. Pradaxa [package insert]. Ridgefibro, CT: Boehringer Ingelheim Pharmaceuticals, Inc;2011.
36. Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, Yang S, Alings M, Kaatz S, Hohnloser SH, Diener HC, Franzosi MG, Huber K, Reilly P, Varrone J, Yusuf S. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: An analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011;123:2363-2372.